Tenet Healthcare Corporation (THC)
Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Tenet (THC)
Tenet (THC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is the Options Market Predicting a Spike in Tenet Healthcare Stock?
Investors need to pay close attention to THC stock based on the movements in the options market lately.
Tenet Healthcare Continues To Win In Q2, But Medicaid Cuts May Threaten Growth Beyond 2026
Tenet Healthcare remains a buy, consistently beating earnings and raising guidance, even as the healthcare sector faces broad pressure from looming Medicaid cuts. Ambulatory segment growth is key, as it is higher margin and less exposed to Medicaid risk than the hospital segment, which faces headwinds post-2026. Medicaid cuts are now law and will hit hardest after 2026, posing significant long-term risk to hospital revenues despite Tenet's restructuring efforts.
Tenet Healthcare Corporation (THC) Q2 2025 Earnings Call Transcript
Tenet Healthcare Corporation (NYSE:THC ) Q2 2025 Earnings Conference Call July 22, 2025 10:00 AM ET Company Participants William McDowell - Vice President of Investor Relations Saumya Sutaria - Chairman & CEO Sun Park - Executive VP & CFO Conference Call Participants Albert Rice - UBS Investment Bank, Research Division Joshua Raskin - Nephron Research LLC Andrew Mok - Barclays Bank PLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Justin Lake - Wolfe Research, LLC Sarah James - Cantor Fitzgerald & Co., Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Ryan Langston - TD Cowen, Research Division John Ransom - Raymond James & Associates, Inc., Research Division Kevin Fischbeck - BofA Securities, Research Division Operator Good morning. Welcome to Tenet Healthcare Second Quarter 2025 Earnings Conference Call.
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.
Tenet (THC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Tenet (THC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tenet Healthcare (THC) Beats Q2 Earnings and Revenue Estimates
Tenet Healthcare (THC) came out with quarterly earnings of $4.02 per share, beating the Zacks Consensus Estimate of $2.84 per share. This compares to earnings of $2.31 per share a year ago.
Tenet Healthcare (THC) Rises Higher Than Market: Key Facts
Tenet Healthcare (THC) concluded the recent trading session at $175.14, signifying a +1.01% move from its prior day's close.
Insights Into Tenet (THC) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Tenet (THC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
